The pediarix market research report is one of a series of new reports that provides pediarix market statistics, including pediarix industry global market size, regional shares, competitors with a pediarix market share, detailed pediarix market segments, market trends and opportunities, and any further data you may need to thrive in the pediarix industry. This pediarix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to the growing prevalence of infectious diseases, increased public awareness about the importance of booster vaccines, rising global immunization rates, growing awareness of preventable diseases, and increasing pediatric population. Major trends in the forecast period include advancements in vaccine delivery systems, emerging cold chain technology for vaccine preservation, advancements in vaccine adjuvants, automation in vaccine manufacturing, and artificial intelligence in vaccine development.
The growing pediatric population is expected to drive the expansion of the pediarix market. Pediatric patients, ranging from newborns to adolescents, require specialized healthcare tailored to their developmental needs. The increase in this population is attributed to factors such as improved healthcare, reduced mortality rates, higher life expectancy, and changes in demographics. Pediarix is used to immunize children against several diseases, ensuring their overall health. For example, a report from the Centers for Disease Control and Prevention in January 2023 showed a 1% rise in registered births in the United States, reaching 3,664,292, compared to the previous year. As the pediatric population continues to grow, it fuels the demand for products such as Pediarix.
The rising incidence of tetanus and diphtheria is also expected to drive growth in the pediarix market. Tetanus, which causes severe muscle spasms, and diphtheria, which leads to the formation of a thick membrane in the throat, are both preventable with vaccines. The increase in these diseases is largely due to lower vaccination rates, healthcare disruptions, inadequate sanitation, and limited access to healthcare services. Pediarix protects against both tetanus and diphtheria by including tetanus toxoid and diphtheria toxoid in its formulation, which help stimulate the immune system to produce antibodies that fight off the harmful toxins from these bacteria. According to the UK Health Security Agency, 328 diphtheria cases were reported in 2023, compared to 253 in the previous year. This uptick in tetanus and diphtheria cases is further driving the demand for Pediarix.
A key trend in the pediarix market is the strategic investment in developing and manufacturing innovative medicines. Such investments are aimed at achieving long-term business goals, such as gaining a competitive edge, expanding market presence, and enhancing operational efficiency. For instance, in July 2023, GlaxoSmithKline (GSK) invested S$343 million to expand its advanced vaccine manufacturing facility in Tuas, Singapore. This expansion, which will be completed by 2025 with commercial production starting in 2027, is focused on producing drug substances for Hepatitis B vaccines. The facility is designed with cutting-edge manufacturing technologies and sustainability features, aligning with GSK's goal of carbon neutrality by 2030. This strategic investment is expected to strengthen GSK’s global vaccine supply and contribute to market growth.
The countries covered in the pediarix market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Pediarix is a combination vaccine that provides protection against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and polio. It is used to immunize infants and young children, typically starting at 6 weeks of age, to offer early protection against these serious diseases.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary clinical indications for Pediarix include routine pediatric immunization, vaccination for infants and toddlers, as well as prevention of hepatitis B and polio. Routine pediatric immunization involves a series of vaccinations given at specific ages to protect children from common and potentially severe infectious diseases. Pediarix is distributed through various channels, including direct distribution, pharmaceutical distributors, online and retail pharmacies, and is administered by healthcare providers in public health programs.
The pediarix market consists of sales of single-dose vials or pre-filled syringes of combinations vaccines, including diphtheria toxoid, tetanus toxoid, acellular pertussis vaccine (aP), hepatitis B vaccine (HBV), and inactivated poliovirus vaccine (IPV). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to the growing prevalence of infectious diseases, increased public awareness about the importance of booster vaccines, rising global immunization rates, growing awareness of preventable diseases, and increasing pediatric population. Major trends in the forecast period include advancements in vaccine delivery systems, emerging cold chain technology for vaccine preservation, advancements in vaccine adjuvants, automation in vaccine manufacturing, and artificial intelligence in vaccine development.
The growing pediatric population is expected to drive the expansion of the pediarix market. Pediatric patients, ranging from newborns to adolescents, require specialized healthcare tailored to their developmental needs. The increase in this population is attributed to factors such as improved healthcare, reduced mortality rates, higher life expectancy, and changes in demographics. Pediarix is used to immunize children against several diseases, ensuring their overall health. For example, a report from the Centers for Disease Control and Prevention in January 2023 showed a 1% rise in registered births in the United States, reaching 3,664,292, compared to the previous year. As the pediatric population continues to grow, it fuels the demand for products such as Pediarix.
The rising incidence of tetanus and diphtheria is also expected to drive growth in the pediarix market. Tetanus, which causes severe muscle spasms, and diphtheria, which leads to the formation of a thick membrane in the throat, are both preventable with vaccines. The increase in these diseases is largely due to lower vaccination rates, healthcare disruptions, inadequate sanitation, and limited access to healthcare services. Pediarix protects against both tetanus and diphtheria by including tetanus toxoid and diphtheria toxoid in its formulation, which help stimulate the immune system to produce antibodies that fight off the harmful toxins from these bacteria. According to the UK Health Security Agency, 328 diphtheria cases were reported in 2023, compared to 253 in the previous year. This uptick in tetanus and diphtheria cases is further driving the demand for Pediarix.
A key trend in the pediarix market is the strategic investment in developing and manufacturing innovative medicines. Such investments are aimed at achieving long-term business goals, such as gaining a competitive edge, expanding market presence, and enhancing operational efficiency. For instance, in July 2023, GlaxoSmithKline (GSK) invested S$343 million to expand its advanced vaccine manufacturing facility in Tuas, Singapore. This expansion, which will be completed by 2025 with commercial production starting in 2027, is focused on producing drug substances for Hepatitis B vaccines. The facility is designed with cutting-edge manufacturing technologies and sustainability features, aligning with GSK's goal of carbon neutrality by 2030. This strategic investment is expected to strengthen GSK’s global vaccine supply and contribute to market growth.
The key company operating in the pediarix market is GlaxoSmithKline plc
North America was the largest region in the pediarix market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pediarix report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.The countries covered in the pediarix market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Pediarix is a combination vaccine that provides protection against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and polio. It is used to immunize infants and young children, typically starting at 6 weeks of age, to offer early protection against these serious diseases.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary clinical indications for Pediarix include routine pediatric immunization, vaccination for infants and toddlers, as well as prevention of hepatitis B and polio. Routine pediatric immunization involves a series of vaccinations given at specific ages to protect children from common and potentially severe infectious diseases. Pediarix is distributed through various channels, including direct distribution, pharmaceutical distributors, online and retail pharmacies, and is administered by healthcare providers in public health programs.
The pediarix market consists of sales of single-dose vials or pre-filled syringes of combinations vaccines, including diphtheria toxoid, tetanus toxoid, acellular pertussis vaccine (aP), hepatitis B vaccine (HBV), and inactivated poliovirus vaccine (IPV). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Pediarix Market Characteristics4. Pediarix Market Trends And Strategies5. Pediarix Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Pediarix Pricing Analysis & Forecasts30. Global Pediarix Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Pediarix Market32. Recent Developments In The Pediarix Market
3. Pediarix Market Biologic Drug Characteristics
6. Global Pediarix Growth Analysis And Strategic Analysis Framework
8. Pediarix Market Segmentation
9. Global Pediarix Epidemiology Of Clinical Indications
10. Pediarix Market Regional And Country Analysis
11. Asia-Pacific Pediarix Market
12. China Pediarix Market
13. India Pediarix Market
14. Japan Pediarix Market
15. Australia Pediarix Market
16. South Korea Pediarix Market
17. Western Europe Pediarix Market
18. UK Pediarix Market
19. Germany Pediarix Market
20. France Pediarix Market
21. Eastern Europe Pediarix Market
22. North America Pediarix Market
23. USA Pediarix Market
24. Canada Pediarix Market
25. South America Pediarix Market
26. Middle East Pediarix Market
27. Africa Pediarix Market
28. Pediarix Market Competitive Landscape And Company Profiles
29. Global Pediarix Market Pipeline Analysis
33. Pediarix Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Pediarix Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on pediarix market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for pediarix ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pediarix market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Clinical Indication: Routine Pediatric Immunization; Infant And Toddler Vaccination; Hepatitis B Prevention; Polio Prevention2) By Sales Channel: Direct Distribution; Pharmaceutical Distributors; Online And Retail Pharmacies
3) By End User: Healthcare Providers; Public Health Programs
Key Companies Profiled: GlaxoSmithKline plc
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- GlaxoSmithKline plc
